ABCR  Vol.2 No.3 , July 2013
Differential Expression of Glu-Tubulin in Basal-Like Phenotype Carcinoma of the Mammary Gland
ABSTRACT

High levels of tubulin expression have been described in a variety of human malignant tumors, and glu-tubulin, in which the C-terminal tyrosine of α-tubulin is removed by tubulin carboxypeptidase. Over-expression has been reported in the malignant tumors of the mammary gland and correlated with poor prognosis immunohistochemically. Furthermore, Nielsen et al. proposed that the use of a panel of four markers (ER, HER 2, CK 5/6, and EGFR) could accurately identify basal-like phenotype carcinoma (BPC) with widely available standard pathologic tools. In our study, major prognostic factors such as patient age, tumor size, histological grade, axillary lymph node metastasis, vessel invasion, and local recurrence in BPC were not significantly different from non BP carcinoma (NBPC). However, the BPC group showed a higher ratio of distant metastasis than that of the NBPC group. In triple-negative carcinoma (TNC) cases, staining for glu-tubulin was observed in 46 cases (63.8%), which consisted of 42 of the 58 BPC patients (72.4%) and 4 of the 14 NBPC patients (28.6%). A significant association was found between the expression of glu-tubulin and BPC, but not NBPC. It seems that our findings also agree with the observation that BPC exhibits aggressive biological behavior and increases the content of glu-tubulin, which plays a greater role in migration and invasion.


Cite this paper
Kuroda, H. , Imai, Y. , Kuroso, K. , Kojima, M. and Ueda, Y. (2013) Differential Expression of Glu-Tubulin in Basal-Like Phenotype Carcinoma of the Mammary Gland. Advances in Breast Cancer Research, 2, 66-71. doi: 10.4236/abcr.2013.23012.
References
[1]   O. C. Rodriguez, A. W. Schaefer, C. A. Mandato, P. Forscher, W. M. Bement and C. M. Waterman-Storer, “Conserved Microtubule-Actin Interactions in Cell Movement and Morphogenesis,” Nature Cell Biology, Vol. 5, No. 7, 2003, pp. 599-609. doi:10.1038/ncb0703-599

[2]   M. Kavallaris, D. Y. Kuo, C. A. Burkhart, D. L. Regl, M. D. Norris, M. Haber and S. B. Horwitz, “Taxol-Resistant Epithelial Ovarian Tumors Are Associated with Altered Expression of Specific Beta-Tubulin Isotypes,” Journal of Clinical Investigation, Vol. 100, No. 5, 1997, pp. 1282-1293. doi:10.1172/JCI119642

[3]   G. Carles, D. Braguer, C. Dumontet, V. Bourgarel, A. Gon?alves, M. Sarrazin, J. B. Rognoni and C. Briand, “Differentiation of Human Colon Cancer Cells Changes the Expression of Beta-Tubulinisotypes and MAPs,” British Journal of Cancer, Vol. 80, No. 8, 1999, pp. 1162-1168. doi:10.1038/sj.bjc.6690481

[4]   P. Sève, S. Isaac, O. Trédan, P. J. Souquet, Y. Pachéco, M. Pérol, L. Lafanéchère, A. Penet, E. L. Peiller and C. Dumontet, “Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy,” Clinical Cancer Research, Vol. 11, No. 15, 2005, pp. 5481-5486. doi:10.1158/1078-0432.CCR-05-0285

[5]   S. Terry, G. Ploussard, Y. Allory, N. Nicolaiew, F. Boissière-Michot, P. Maillé, L. Kheuang, E. Coppolani, A. Ali, F. Bibeau, S. Culine, R. Buttyan, A. de la Taille and F. Vacherot, “Increased Expression of Class III Beta-Tubulin in Castration-Resistant Human Prostate Cancer,” British Journal of Cancer, Vol. 101, No. 6, 2009, pp. 951-956. doi:10.1038/sj.bjc.6605245

[6]   C. Bernard-Marty, I. Treilleux, C. Dumontet, F. Cardoso, A. Fellous, D. Gancberg, M. C. Bissery, M. Paesmans, D. Larsimont, M. J. Piccart and A. Di Leo, “MicrotubuleAssociated Parameters as Predictive Markers of Docetaxel Activity in Advanced Breast Cancer Patients: Results of a Pilot Study,” Clinical Breast Cancer, Vol. 3, No. 5, 2002, pp. 341-345. doi:10.3816/CBC.2002.n.037

[7]   A. Mialhe, L. Lafanechère, I. Treilleux, N. Peloux, C. Dumontet, A. Brémond, M. H. Panh, R. Payan, J. Wehland, R. L. Margolis and D. Job, “Tubulin Detyrosination Is a Frequent Occurrence in Breast Cancers of Poor Prognosis,” Cancer Research, Vol. 61, No. 13, 2001, pp. 5024-5027.

[8]   H. Kuroda, K. Saito, M. Kuroda and Y. Suzuki, “Differential Expression of Glu-Tubulin in Relation to Mammary Gland Disease,” Virchows Archives, Vol. 457, No. 4, 2010, pp. 477-482. doi:10.1007/s00428-010-0955-z

[9]   S. Cleator, W. Heller and R. C. Coombes, “Triple-Negative Breast Cancer: Therapeutic Options,” Lancet Oncology, Vol. 8, No. 3, 2007, pp. 235-244. doi:10.1016/S1470-2045(07)70074-8

[10]   T. O. Nielsen, F. D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler, L. A. Akslen, J. Ragaz, A. M. Gown, C. B. Gilks, M. van de Rijn and C. M. Perou, “Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma,” Clinical Cancer Research, Vol. 10, No. 16, 2004, pp. 5367-5374. doi:10.1158/1078-0432.CCR-04-0220

[11]   E. A. Rakha, M. E. El-Sayed, A. R. Green, A. H. Lee, J. F. Robertson and I. O. Ellis, “Prognostic Markers in TripleNegative Breast Cancer,” Cancer, Vol. 109, No. 1, 2007, pp. 25-32. doi:10.1002/cncr.22381

[12]   K. P. Siziopkou and M. Cobleigh, “The Basal Subtype of Breast Carcinomas May Represent the Group of Breast Tumors That Could Benefit from EGFR-Targeted Therapies,” Breast, Vol. 16, No. 1, 2007, pp. 104-107. doi:10.1016/j.breast.2006.09.003

[13]   M. Sasa, Y. Bando, M. Takahashi, T. Hirose and T. Nagao, “Screening for Basal Marker Expression Is Necessary for Decision of Therapeutic Strategy for Triple-Negative Breast Cancer,” Journal of Surgical Oncology, Vol. 97, No. 1, 2008, pp. 30-34. doi:10.1002/jso.20906

[14]   C. W. Elston and I. O. Ellis, “Pathological Prognostic Factors in Breast Cancer. I. The Value of Histological Grade in Breast Cancer: Experience from a Large Study with Long-Term Follow-Up,” Histopathology, Vo1. 19, No. 5, 1991, pp. 403-410.

[15]   G. G. Gundersen and J. C. Bulinski, “Microtubule Arrays in Differentiated Cells Contain Elevated Levels of a PostTranslationally Modified Form of Tubulin,” European Journal of Cell Biology, Vol. 42, No. 2, 1986, pp. 288-294.

[16]   T. E. Kreis, “Microtubules Containing Detyrosinated Tubulin Are Less Dynamic,” EMBO Journal, Vol. 6, No. 9, 1987, pp. 2597-2606.

[17]   E. Schulze, D. J. Asai, J. C. Bulinski and M. Kirschner, “Posttranslational Modification and Microtubule Stability,” Journal of Cell Biology, Vol. 105, No. 5, 1987, pp. 2167-2177. doi:10.1083/jcb.105.5.2167

[18]   A. R. Prescott, M. Vestberg and R. M. Warn, “Microtubules Rich in Modified Alpha-Tubulin Characterize the Tail Processes of Motile Fibroblasts,” Journal of Cell Science, Vol. 94, No. 2, 1989, pp. 227-236.

[19]   C. M. Perou, T. S?rlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. L?nning, A. L. B?rresen-Dale, P. O. Brown and D. Botstein, “Molecular Portraits of Human Breast Tumours,” Nature, Vol. 406, No. 6797, 2000, pp. 747-752. doi:10.1038/35021093

[20]   T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. E. L?nning and A. L. B?rresen-Dale, “Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications,” Proceedings of National Academy Science of the USA, Vol. 98, No. 19, 2001, pp. 10869-10874. doi:10.1073/pnas.191367098

[21]   T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. L?nning, P. O. Brown, A. L. B?rresen-Dale and D. Botstein, “Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets,” Proceedings of National Academy Science of the USA, Vol. 100, No. 14, 2003, pp. 8418-8423. doi:10.1073/pnas.0932692100

[22]   J. D. Brenton, L. A. Carey, A. A. Ahmed and C. Caldas, “Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?” Journal of Clinical Oncology, Vol. 23, No. 29, 2005, pp. 7350-7360. doi:10.1200/JCO.2005.03.3845

[23]   B. G. Haffty, Q. Yang, M. Reiss, T. Kearney, S. A. Higgins, J. Weidhaas, L. Harris, W. Hait and D. Toppmeyer, “Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer,” Journal of Clinical Oncology, Vol. 24, No. 36, 2006, pp. 5652-5657.

[24]   T. Wittmann and C. M. Waterman-Storer, “Cell Motility: Can Rho GTPases and Microtubules Point the Way?” Journal of Cell Science, Vol. 114, No. 21, 2001, pp. 3795-3803.

[25]   I. R. Nabi, “The Polarization of the Motile Cell,” Journal of Cell Science, Vol. 112, No. 12, 1999, pp. 1803-1811.

[26]   Y. Zheng, “G Protein Control of Microtubule Assembly,” Annual Reviews Cell and Developmental Biology, Vol. 20, 2004, pp. 867-894. doi:10.1146/annurev.cellbio.20.012103.094648

[27]   G. G. Gundersen and J. C. Bulinski, “Selective Stabilization of Microtubules Oriented toward the Direction of Cell Migration,” Proceedings of National Academy Science of the USA, Vol. 85, No. 16, 1988, pp. 5946-5950. doi:10.1073/pnas.85.16.5946

[28]   Y. Wen, C. H. Eng, J. Schmoranzer, N. Cabrera-Poch, E. J. Morris, M. Chen, B. J. Wallar, A. S. Alberts and G. G. Gundersen, “EB1 and APC Bind to mDia to Stabilize Microtubules Downstream of Rho and Promote Cell Migration,” Nature Cell Biology, Vol. 6, No. 9, 2004, pp. 820-830. doi:10.1038/ncb1160

[29]   D. G. Hicks, S. M. Short, N. L. Prescott, S. M. Tarr, K. A. Coleman, B. J. Yoder, J. P. Crowe, T. K. Choueiri, A. E. Dawson, G. T. Budd, R. R. Tubbs, G. Casey and R. J. Weil, “Breast Cancers with Brain Metastases Are More Likely to Be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR,” American Journal of Surgical Pathology, Vol. 30, No. 19, 2006, pp. 1097-1104. doi:10.1097/01.pas.0000213306.05811.b9

[30]   H. Tsuda, T. Takarabe, F. Hasegawa, T. Fukutomi and S. Hirohashi, “Large, Central Acellular Zones Indicating Myoepithelial Tumor Differentiation in High-Grade Invasive Ductal Carcinomas as Markers of Predisposition to Lung and Brain Metastases,” American Journal of Surgical Pathology, Vol. 24, No. 2, 2000, pp. 197-202. doi:10.1097/00000478-200002000-00005

 
 
Top